Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare immunodeficiency syndrome characterized by the decrease of the CD4-positive lymphocytes below 300 per cubic millimeter in the absence of identifiable immunodeficiency causes. Patients with this syndrome are at an increased risk of opportunistic infections.
1 clinical trial registered, 1 recruiting. Interventions under study include drug therapy and biologic therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
3 publications have been identified in PubMed for idiopathic CD4-positive T-lymphocytopenia. Research spans Case Report / Case Series (100%).
Li B (2025). [PMID: 39866372](https://pubmed.ncbi.nlm.nih.gov/39866372/). *IDCases*. [Case Report / Case Series]
Wang T (2025). [PMID: 40652180](https://pubmed.ncbi.nlm.nih.gov/40652180/). *BMC Nephrol*. [Case Report / Case Series]
Esmailian A (2024). [PMID: 39380982](https://pubmed.ncbi.nlm.nih.gov/39380982/). *J Allergy Clin Immunol Glob*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:31 PM UTC